| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Azido-PEG6-NHS ester contains an azide group for click chemistry and an NHS ester for amine coupling. The NHS ester reacts with primary amines to form stable amide bonds, enabling conjugation to proteins, peptides, and other amine-containing molecules. The azide group enables CuAAC click chemistry with alkyne-bearing molecules. The PEG spacer enhances solubility and reduces aggregation.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1]. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [2].
In vitro, Azido-PEG6-NHS ester is used as a linker for the synthesis of ADCs, PROTACs, and other bioconjugates. The NHS ester enables efficient conjugation to antibodies and other proteins. The azide group enables further functionalization via click chemistry. The PEG spacer enhances the solubility and stability of the resulting conjugates. |
| ln Vivo |
In vivo, Azido-PEG6-NHS ester is not administered directly but is used to synthesize ADCs and PROTACs that are evaluated in animal models. The PEG spacer enhances the solubility and stability of the resulting conjugates. The compound's role as a linker in ADC and PROTAC synthesis has been validated in various preclinical studies.
|
| Enzyme Assay |
In cell-free biochemical assays, Azido-PEG6-NHS ester is evaluated for its ability to serve as a linker in conjugation reactions. The NHS ester enables efficient conjugation to primary amines, while the azide group enables click chemistry. The compound's purity and molecular weight are characterized using analytical techniques.
|
| Cell Assay |
In cellular assays, the ADCs or PROTACs synthesized using Azido-PEG6-NHS ester are tested for their biological activity. The PEG linker's effect on cellular uptake, intracellular trafficking, and activity is assessed. The compound itself is not biologically active and serves only as a linker.
|
| Animal Protocol |
Animal models for Azido-PEG6-NHS ester involve evaluating the ADCs or PROTACs synthesized using this linker. The resulting conjugates are tested in disease models. The PEG linker's effect on pharmacokinetics, biodistribution, and efficacy is assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Azido-PEG6-NHS ester are not typically reported. The compound is a linker rather than a therapeutic agent. The CAS number is 2055014-64-5. Standard handling procedures for PEG linkers apply.
|
| Toxicity/Toxicokinetics |
Toxicity data for Azido-PEG6-NHS ester are limited. Standard safety precautions for handling laboratory chemicals apply. The azide group may pose a hazard. The compound is for research use only.
|
| References | |
| Additional Infomation |
Azido-PEG6-NHS ester is a heterobifunctional PEG linker for ADC and PROTAC synthesis. It contains an azide group for click chemistry and an NHS ester for amine coupling. The PEG spacer enhances solubility and stability. The CAS number is 2055014-64-5.
|
| Molecular Formula |
C19H32N4O10
|
|---|---|
| Molecular Weight |
476.478185653687
|
| Exact Mass |
476.211
|
| CAS # |
2055014-64-5
|
| PubChem CID |
77078479
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
-0.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
33
|
| Complexity |
599
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)N(C1=O)OC(=O)CCOCCOCCOCCOCCOCCOCCN=[N+]=[N-]
|
| InChi Key |
WXKOAPGNZNSYPW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H32N4O10/c20-22-21-4-6-28-8-10-30-12-14-32-16-15-31-13-11-29-9-7-27-5-3-19(26)33-23-17(24)1-2-18(23)25/h1-16H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~209.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0987 mL | 10.4936 mL | 20.9872 mL | |
| 5 mM | 0.4197 mL | 2.0987 mL | 4.1974 mL | |
| 10 mM | 0.2099 mL | 1.0494 mL | 2.0987 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
